Evidence map›Paper›PMID 28465156›Full record

ArticleEBioMedicine2017

Plasma Viral miRNAs Indicate a High Prevalence of Occult Viral Infections.

Enrique Fuentes-Mattei, Dana Elena Giza, Masayoshi Shimizu, Cristina Ivan, John T Manning, Stefan Tudor, Maria Ciccone, Osman Aykan Kargin, Xinna Zhang, Pilar Mur and 9 more

Open access · goldAbstract read
In one paragraph

Article in EBioMedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. The non-coding RNome after splenectomy.Journal of cellular and molecular medicine · 2019
    Article
  10. Cell communication and signaling: how to turn bad language into positive one.Journal of experimental & clinical cancer research : CR · 2019
    Article
  11. The Implications of the Long Non-Coding RNAInternational journal of molecular sciences · 2019
    Review
  12. Observational
  13. Clinical utility of circulating non-coding RNAs - an update.Nature reviews. Clinical oncology · 2018
    Review
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 5 countries.

Enrique Fuentes-MatteiDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dana Elena GizaDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Masayoshi ShimizuDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Cristina IvanDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The RNA Interference and Non-Coding RNA Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
John T ManningDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, US.
Stefan TudorUMF Carol Davila Bucharest, Romania and Fundeni Hospital, Bucharest, Romania.
Maria CicconeDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Leukemia Department, Santa Anna Hospital, University of Ferrara, Ferrara, Italy.
Osman Aykan KarginDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Hacettepe University Faculty of Medicine, Ankara, Turkey.
Xinna ZhangThe RNA Interference and Non-Coding RNA Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pilar MurHereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Nayra Soares do AmaralDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Molecular Morphology Laboratory, AC Camargo Cancer Center, São Paulo 01508-010, Brazil.
Meng ChenDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jeffrey J TarrandDepartment of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Florea LupuCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Alessandra FerrajoliDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael J KeatingDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Catalin VasilescuUMF Carol Davila Bucharest, Romania and Fundeni Hospital, Bucharest, Romania.
Sai-Ching Jim YeungDepartment of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
George A CalinDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The RNA Interference and Non-Coding RNA Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: gcalin@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USInstitut Català d'Oncologia · ESOklahoma Medical Research Foundation · US

Funding

Translation of immunologic technologies from basic research into pre-clinical nonU19AI062629 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI THOMPSON, LINDA F · 2004 to 2023
$56.2M
Novel extra cellular RNA-based combinatorial RNA inhibition therapyUH3TR000943 · NCATS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CALIN, GEORGE A., LOPEZ-BERESTEIN, GABRIEL · 2015 to 2017
$3.2M
Protein-coding and non-coding RNA biomarkers for early detection of CLLR01CA182905 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ABRUZZO, LYNNE V., CALIN, GEORGE A. · 2014 to 2018
$2.9M
FXI and SepsisR01GM116184 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI LUPU, FLOREA, MCCARTY, OWEN J · 2015 to 2018
$1.9M
NCATS NIH HHS UH3 TR000943NCI NIH HHS R01 CA182905NIAID NIH HHS U19 AI062629NIGMS NIH HHS R01 GM116184
6 · The paper itself

Abstract

Prevalence of Kaposi sarcoma-associated herpesvirus (KSHV/HHV-8) varies greatly in different populations. We hypothesized that the actual prevalence of KSHV/HHV8 infection in humans is underestimated by the currently available serological tests. We analyzed four independent patient cohorts with post-surgical or post-chemotherapy sepsis, chronic lymphocytic leukemia and post-surgical patients with abdominal surgical interventions. Levels of specific KSHV-encoded miRNAs were measured by reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and KSHV/HHV-8 IgG were measured by immunoassay. We also measured specific miRNAs from Epstein Barr Virus (EBV), a virus closely related to KSHV/HHV-8, and determined the EBV serological status by ELISA for Epstein-Barr nuclear antigen 1 (EBNA-1) IgG. Finally, we identified the viral miRNAs by in situ hybridization (ISH) in bone marrow cells. In training/validation settings using independent multi-institutional cohorts of 300 plasma samples, we identified in 78.50% of the samples detectable expression of at least one of the three tested KSHV-miRNAs by RT-qPCR, while only 27.57% of samples were found to be seropositive for KSHV/HHV-8 IgG (P<0.001). The prevalence of KSHV infection based on miRNAs qPCR is significantly higher than the prevalence determined by seropositivity, and this is more obvious for immuno-depressed patients. Plasma viral miRNAs quantification proved that EBV infection is ubiquitous. Measurement of viral miRNAs by qPCR has the potential to become the "gold" standard method to detect certain viral infections in clinical practice.

Indexed as

MicroRNAsRNA, ViralViral LoadAntibodies, ViralCohort StudiesEnzyme-Linked Immunosorbent AssayHerpesvirus 8, HumanHumansImmunoglobulin GIn Situ HybridizationLeukocyte CountLymphocyte CountPrevalenceReal-Time Polymerase Chain ReactionReproducibility of ResultsVirus DiseasesAntibodies, ViralImmunoglobulin GMicroRNAsRNA, ViralEBVHHV4HHV8Infection prevalenceKSHVViral miRNAs

Identifiers

PMID28465156
PMCPMC5478184
OpenAlexW2607153668

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.